STX is a commercial-stage pharmaceutical company delivering specialty products that address patients’ unmet medical needs, with an initial focus on treating iron deficiency (ID) with Feraccru®/Accrufer®. FDA approval of Accrufer with a broad label in the US opens up a current market worth over $1bn in intravenous (IV) iron alone. This event will transition the company from the early growth stage illustrated by its 2019 interim results into a global company by 2020. STX is in ongoing discussions with a number of potential partners for US commercialisation – a deal that represents the next major valuation inflection point.
02 Sep 2019
FDA approval ushers in a new era for Shield
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
FDA approval ushers in a new era for Shield
Shield Therapeutics Plc (STX:LON) | 1.4 0 0.0% | Mkt Cap: 11.1m
- Published:
02 Sep 2019 -
Author:
Martin Hall -
Pages:
11
STX is a commercial-stage pharmaceutical company delivering specialty products that address patients’ unmet medical needs, with an initial focus on treating iron deficiency (ID) with Feraccru®/Accrufer®. FDA approval of Accrufer with a broad label in the US opens up a current market worth over $1bn in intravenous (IV) iron alone. This event will transition the company from the early growth stage illustrated by its 2019 interim results into a global company by 2020. STX is in ongoing discussions with a number of potential partners for US commercialisation – a deal that represents the next major valuation inflection point.